Hyperactivity News and Research

RSS

Surgery may not be the best option for children with obstructive sleep apnea

For children with obstructive sleep apnea, standard care often includes a tonsillectomy and adenoidectomy. But researchers at Saint Louis University say further research is needed to determine if surgery is the best option for these patients.

5 Nov 2009

Medidata Solutions announces multi-year contract extension with Shire

Medidata Solutions, a leading global provider of hosted clinical development solutions, today announced a multi-year contract extension with Shire plc for use of Medidata Grants Manager™ and CRO Contractor™ benchmarking and analysis tools for investigator site and contract research organization (CRO) trial budget planning and forecasting.

4 Nov 2009

Marianjoy Rehabilitation Hospital offers behavioral testing for children

Marianjoy Rehabilitation Hospital now provides neuropsychological assessments and testing for children ages 5 to 18 who are exhibiting behavioral issues or academic difficulties.

4 Nov 2009

Cost of ADHD clinical trials can be reduced by implementing Quotient ADHD System

BioBehavioral Diagnostics Company announced today that its poster was presented Friday, October 30, 2009 after it was accepted via a rigorous peer-review process and included as a New Research Poster presentation at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP) in Honolulu, HI, October 27-November 1, 2009.

4 Nov 2009

Phase 1 study of STX107 for Fragile X syndrome begins

NIH-supported scientists at Seaside Therapeutics in Cambridge, Mass., are beginning a clinical trial of a potential medication designed to correct a central neurochemical defect underlying Fragile X syndrome, the most common inherited cause of intellectual disability. There has to date been no medication that could alter the disorder's neurologic abnormalities. The study will evaluate safety, tolerability, and optimal dosage in healthy volunteers.

3 Nov 2009

Shire to present key data on ADHD treatments at national psychiatric meeting

Shire plc, the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV- (guanfacine) Extended Release Tablets, Vyvanse- (lisdexamfetamine dimesylate) Capsules CII, and Daytrana- (methylphenidate transdermal system) CII, at a national meeting of psychiatrists to be held October 27 - November 1 in Honolulu.

31 Oct 2009

Shire announces Phase IIIb study results of Daytrana

Shire plc, the global specialty biopharmaceutical company, today announced findings at a major medical meeting from a Phase IIIb study of the tolerability and effectiveness of Daytrana® (methylphenidate transdermal system) in adolescents aged 13 to 17 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD).

31 Oct 2009

New study results of INTUNIV presented at a major psychiatric medical meeting

Shire plc, the global specialty biopharmaceutical company, announced new study results on INTUNIV- (guanfacine) Extended Release Tablets, at a major psychiatric medical meeting today.

31 Oct 2009

Shire announces third quarter 2009 financial results

Shire plc, the global specialty biopharmaceutical company, announces results for the three months to September 30, 2009.

31 Oct 2009

Shire's ADHD treatment data to be presented at the Honolulu psychiatric meeting

Shire plc, the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV(TM) (guanfacine) Extended Release Tablets, Vyvanse®( ) (lisdexamfetamine dimesylate) Capsules CII, and Daytrana®( ) (methylphenidate transdermal system) CII, at a national meeting of psychiatrists to be held October 27 - November 1 in Honolulu.

30 Oct 2009

Study links low maternal folate levels with attention-deficit/hyperactivity problems in children

It has long been suggested that healthy folate (the natural form of folic acid) levels in expectant mothers goes hand in hand with healthy nervous system development in their children. A study published in an upcoming issue of the Journal of Child Psychology and Psychiatry finds that low maternal folate levels is linked to the development of attention-deficit/hyperactivity problems in children at age seven to nine years.

29 Oct 2009

Study of ‘real-life’ experiences of patients undergoing 5-ASA treatment for ulcerative colitis

InfoMedics, Inc., a company that engages patients and physicians to communicate better through the delivery of treatment feedback, has poster presentations at three industry conferences in October 2009. All of these studies provide a unique look at real-life patient feedback regarding experiences with medications for chronic conditions including ulcerative colitis (UC) and attention-deficit/hyperactivity disorder (ADHD) in adults and children.

28 Oct 2009

Two-year trial to test effectiveness of behavioral psychotherapy for young adolescents with autism

The USF Health Rothman Center for Neuropsychiatry in St. Petersburg, FL, is conducting a two-year federal trial testing the effectiveness of behavioral psychotherapy in treating anxiety among young adolescents with autism.

28 Oct 2009

New therapy for decreasing anxiety and improving psychological well-being in children

A group of investigators of the University of Bologna suggest a new way of approaching emotional disturbances in children by improving their psychological well-being. The study is published in the current issue of Psychotherapy and Psychosomatics.

27 Oct 2009

Deep brain stimulation: New treatment option for people with severe Tourette syndrome

Deep brain stimulation may be a safe and effective treatment for Tourette syndrome, according to research published in the October 27, 2009, print issue of Neurology®, the medical journal of the American Academy of Neurology.

27 Oct 2009

FDA grants five-year New Chemical Entity exclusivity to VYVANSE

Shire plc, the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).

26 Oct 2009

Free, public lecture on hyperactivity

Biologist Theodore Garland will give an hour-long lecture, titled "Born to Run: Evolution of Hyperactivity in Mice," at 7 p.m., Thursday, Oct. 29, in the University Theatre on the UC Riverside campus. Doors open at 6 p.m. Seating is open.

24 Oct 2009

Shire announces new pharmacokinetic data of ADHD medication

Shire plc, the global specialty biopharmaceutical company, announced new data about the pharmacokinetics of its Attention-Deficit/Hyperactivity Disorder (ADHD) medication, Vyvanse- (lisdexamfetamine dimesylate) Capsules CII, which showed that Vyvanse provided similar concentrations of its active medication in the blood when administered either intranasally or when administered orally.

23 Oct 2009

Quality of U.S. health care was virtually stagnant in 2008, says NCQA report

A report released today by the National Committee for Quality Assurance (NCQA) finds that the quality of U.S. health care was virtually stagnant in 2008, a disturbing slowdown after a decade of improvements. The across-the-board trend was seen in care provided to people with private insurance coverage as well as in Medicare and Medicaid.

23 Oct 2009

KemPharm commences KP106 Phase 1 clinical trial for ADHD

KemPharm, Inc. today announced that it has commenced a Phase 1 clinical trial in healthy volunteers of its novel prodrug compound, KP106, which is in development for the treatment of attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of d-amphetamine and a ligand, is the lead investigational candidate from KemPharm’s proprietary ligand activated therapy (LAT) platform, which creates improved versions of FDA-approved drugs. KemPharm began the KP106 program in 2007 and has initiated the Phase 1 clinical trial of this candidate in less than 24 months.

22 Oct 2009